TrialAnnals of oncology : official journal of the European Society for Medical Oncology2014

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

M Aapro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.